Press Releases
Stay up to date with press releases covering announcements, company news, product launches, and business updates.
Publish your press release
NextCure Provides Business Update and Reports Third Quarter 2026 Financial Results
GlobeNewswire, Inc.
Advancing Toward Stockholder Approval of Proposed Merger with Avere Therapeutics Supported by Approximately $820 Million of Committed Financing S-4 Declared Effective by SEC; Stockholder Vote Scheduled for December 9, 2026 BALTIMORE, Md., Nov. 10,...
Eupraxia Pharmaceuticals Reports Third Quarter 2026 Financial Results
GlobeNewswire, Inc.
Reached target enrollment of 120 patients in the Phase 2b placebo-controlled blinded portion of the RESOLVE trial evaluating EP-104GI for Eosinophilic Esophagitis (EoE) Phase 2b interim analysis expected in December 2026 Cash runway into the...
Braveheart Bio Reports Third Quarter 2026 Financial Results and Provides Business Update
GlobeNewswire, Inc.
52-week data presented at AHA Scientific Sessions 2026 further strengthen BHB-1893’s potential differentiation, with encouraging clinical activity and support for a highly simplified dosing regimen LIONHEART-HCM oHCM Phase 3 enrolling with interim...
Kura Oncology Reports Third Quarter 2026 Financial Results and Corporate Update
GlobeNewswire, Inc.
– KOMZIFTI® (ziftomenib) net product revenue grew 53% sequentially to $13.9 million; new patient starts increased 30% and total prescriptions grew 65% – – KOMZIFTI maintained majority share of new patient starts of the menin inhibitor class in the...
Metagenomi Therapeutics Announces FDA Clearance of Investigational New Drug Application for MGX-001 and Reports Third Quarter 2026 Financial Results
GlobeNewswire, Inc.
FDA clearance enables initiation of a first-in-human Phase 1/2 trial of MGX-001 in patients with hemophilia A MGX-001 is designed to deliver durable, endogenous Factor VIII (FVIII) activity from a one-time treatment for adults and children Company...
Corbus Pharmaceuticals Reports Q3 2026 Financial Results and Provides a Corporate Update
GlobeNewswire, Inc.
Dosed first patient in TEMPO-1 registrational study of sutantatug envedotin (CRB-701) in patients with 2L+ oropharyngeal cancer Reported topline data from the CANYON-1 Phase 1b obesity study of CRB-913 demonstrating mean weight loss of 5% after 12...
Autolus Therapeutics Reports Third Quarter 2026 Financial Results and Business Updates
GlobeNewswire, Inc.
Company reports AUCATZYL® (obecabtagene autoleucel; obe-cel) net product revenue of $41.2 million, an increase of 95% year-over-year; now expects full-year 2026 AUCATZYL net product revenue to be at or exceeding upper end of $150 million from...
Select Home Warranty Reports Thanksgiving Appliance Claims Calls Surge
EIN Presswire
Holiday Cooking Demands Trigger 2.70x Surge in Oven Service Requests and 2.56x Spike in Garbage Disposal Leaks MAHWAH, NJ, UNITED STATES, November 10, 2026 /EINPresswire.com/ -- As millions of American households prepare to host Thanksgiving...
Annual Report Shows Continued Long-Term Decline in High-Risk Pesticide Use
California Department of Pesticide Regulation
WHAT YOU NEED TO KNOW: The California Department of Pesticide Regulation (DPR) has released its annual Pesticide Use Report for 2024. While pesticide use between 2023 to 2024 increased slightly, the overall ten-year trend shows decreases in use of...
Taco Mac Restaurant Group Selects BeerBoard to Modernize Beverage Operations with AI-Powered Alcohol Intelligence
EIN Presswire
ALPHARETTA, GA, UNITED STATES, November 10, 2026 /EINPresswire.com/ -- Georgia-based wings and sports-bar chain replaces legacy system to gain real-time visibility, smarter ordering, and stronger margins Taco Mac Restaurant Group, the longtime...
PMV Pharmaceuticals Reports Third Quarter 2026 Financial Results and Corporate Highlights
GlobeNewswire, Inc.
Pivotal Phase 2 rezatapopt PYNNACLE data to be featured in late-breaking oral presentation at ENA 2026 Announced closing of oversubscribed $50 million public offering of securities Rezatapopt NDA submission for platinum-resistant/refractory...
Arbutus Reports Third Quarter 2026 Financial Results and Provides Corporate Update
GlobeNewswire, Inc.
Maintained strong financial position with cash, cash equivalents and marketable securities of $337.5M as of September 30, 2026, including receipt of cash dividend of $67.3M from Genevant Successfully returned $230M of capital to shareholders via...
Cellectar Biosciences Reports Third Quarter 2026 Financial Results and Provides Corporate Updates
GlobeNewswire, Inc.
Presented updated data at the International Workshop for Waldenström Macroglobulinemia (IWWM) supporting the planned accelerated approval strategy for iopofosine I 131 in Waldenström macroglobulinemia (WM) On track to dose first patients in the...
Hemab Therapeutics Reports Third Quarter 2026 Financial Results and Provides Corporate Update
GlobeNewswire, Inc.
Dosed first participant in Phase 1 clinical trial of HMB-003 for management of heavy menstrual bleeding, a condition affecting more than 23 million women in the U.S. alone Announced data showing HMB-003 reduced severe menstrual bleeding in a...
Olema Oncology Reports Third Quarter 2026 Financial and Operating Results
GlobeNewswire, Inc.
On track to announce top-line data from the pivotal Phase 3 OPERA-01 trial in the first quarter of 2027 Continued strong enrollment in the pivotal Phase 3 OPERA-02 trial and the Phase 1b/2 study of OP-3136 Appointed Jason O’Byrne, MBA, as Chief...
Legend Biotech Reports Third Quarter 2026 Results and Recent Highlights
GlobeNewswire, Inc.
CARVYKTI® (ciltacabtagene autoleucel; cilta-cel) net trade sales increased 36% versus third quarter of 2025 to approximately $710 million Half of CARTITUDE-2 Cohort A patients remained alive and progression-free without further anti-myeloma...
Upstream Bio Reports Third Quarter 2026 Financial Results and Highlights Continued Progress
GlobeNewswire, Inc.
– Company plans to initiate Phase 3 trials in both severe asthma and CRSwNP in the first quarter of 2027 – – Prioritizing Phase 3 development strategy designed to deliver best-in-class efficacy and convenient quarterly dosing – WALTHAM, Mass.,...
Humacyte Reports Third Quarter 2026 Results, Highlighted by More Than Doubling Symvess Revenue and Expanding Commercial Adoption
GlobeNewswire, Inc.
– Commercial adoption of Symvess® accelerated during the third quarter with sales totaling $1.0 million, a 151% increase over the 2nd quarter. – Symvess commercial momentum continued into the fourth quarter, with October 2026 sales totaling $0.8...
Cullinan Therapeutics Provides Corporate Update and Reports Third Quarter 2026 Financial Results
GlobeNewswire, Inc.
CLN-978 (CD19 TCE) multi-dose regimen data in SLE, RA, and Sjögren’s disease will be shared in December Velinotamig (BCMA TCE) data presented at ACR Convergence 2026; global Phase 1/2 study in autoimmune cytopenias initiated CLN-049 (FLT3 TCE)...
CalciMedica Reports Third Quarter 2026 Financial Results and Provides Clinical & Corporate Updates
GlobeNewswire, Inc.
Auxora Phase 1b proof-of-concept data in pulmonary hypertension (PH) and CM5480 IND submission both anticipated in mid-2027 Cash, cash equivalents and short-term investments of $13.8 million as of September 30, 2026; cash expected to fund current...
Sign up for:
Food & Beverage Report
The daily local news briefing you can trust. Every day. Subscribe now.
Check Your Email!
We sent a one-time activation link to: .
Confirm it's you by clicking the email link.
If the email is not in your inbox, check spam or try again.
Welcome back!
is already signed up. Check your inbox for updates.